These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 2871858)
61. [Injectable temesta, anxiety and distress]. Breulet M; Parent M; Bourdouxhe S; Bobon J Acta Psychiatr Belg; 1974 May; 74(3):278-93. PubMed ID: 4156148 [No Abstract] [Full Text] [Related]
62. Buspirone: a new type of anxiolytic. Dommisse CS; DeVane CL Drug Intell Clin Pharm; 1985 Sep; 19(9):624-8. PubMed ID: 2864225 [TBL] [Abstract][Full Text] [Related]
64. The risk of pharmacological dependence with buspirone. Tyrer P; Murphy S; Owen RT Br J Clin Pract Suppl; 1985 May; 38():91-4. PubMed ID: 2862909 [No Abstract] [Full Text] [Related]
65. Buspirone treatment of anxiety associated with pharyngeal dysphagia in a four-year-old. Hanna GL; Feibusch EL; Albright KJ J Child Adolesc Psychopharmacol; 1997; 7(2):137-43. PubMed ID: 9334898 [TBL] [Abstract][Full Text] [Related]
66. A combined treatment approach to anxiety in the medically ill. Wise MG; Griffies WS J Clin Psychiatry; 1995; 56 Suppl 2():14-9. PubMed ID: 7844102 [TBL] [Abstract][Full Text] [Related]
67. I have heard that buspirone regularly affects various blood tests. Is this so? Shader RI J Clin Psychopharmacol; 1996 Apr; 16(2):194. PubMed ID: 8690840 [No Abstract] [Full Text] [Related]
68. Clinical studies of buspirone. Schuckit MA Psychopathology; 1984; 17 Suppl 3():61-8. PubMed ID: 6150509 [TBL] [Abstract][Full Text] [Related]
70. Failure of buspirone to protect against lorazepam withdrawal symptoms. Jerkovich GS; Preskorn SH JAMA; 1987 Jul; 258(2):204-5. PubMed ID: 2885432 [No Abstract] [Full Text] [Related]
71. Buspirone for the treatment of anxiety in patients with chronic obstructive airways disease. Alderman CP; Frith PA; Ben-Tovim DI J Clin Psychopharmacol; 1996 Oct; 16(5):410-1. PubMed ID: 8889916 [No Abstract] [Full Text] [Related]
72. Evaluation of the safety and side effects of antianxiety agents. Schnabel T Am J Med; 1987 May; 82(5A):7-13. PubMed ID: 2884874 [TBL] [Abstract][Full Text] [Related]
73. Assessment of addiction liability of benzodiazepines and buspirone. Perry PJ Drug Intell Clin Pharm; 1985 Sep; 19(9):657-9. PubMed ID: 2864227 [No Abstract] [Full Text] [Related]
74. Sertraline for treatment of post-stroke anxiety. Rao V; Bergey A; Rosenberg P J Neuropsychiatry Clin Neurosci; 2012; 24(2):E22. PubMed ID: 22772684 [No Abstract] [Full Text] [Related]
75. Etifoxine: too many serious adverse effects. Prescrire Int; 2013 Mar; 22(136):73. PubMed ID: 23593696 [No Abstract] [Full Text] [Related]
77. A dose range-finding study of buspirone in geriatric patients with symptoms of anxiety. Singh AN; Beer M J Clin Psychopharmacol; 1988 Feb; 8(1):67-8. PubMed ID: 3351003 [No Abstract] [Full Text] [Related]
78. Comment: Addiction liability of benzodiazepines and buspirone. Nelson RC Drug Intell Clin Pharm; 1986 Mar; 20(3):233-4. PubMed ID: 2869928 [No Abstract] [Full Text] [Related]
79. [Efficacy of aphobazole in the treatment of anxiety disorders in patients with chronic cerebro-vascular insufficiency]. Sholomov II; Lutoshkina EB; Salina EA Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(6):75-7. PubMed ID: 18800419 [No Abstract] [Full Text] [Related]
80. Observations on the continuous use of trioxazine. Haits G Ther Hung; 1976; 24(4):145-7. PubMed ID: 13509 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]